AUTHORS
Weiming Li, Xiaodong Wang, MD2, Sujun Gao3, Xiaojing Yan, MD, PhD4, Zhenya Hong5, Zhenfang Liu, DO6, Yanli Zhang, MD7, Yang Yu8, Rili Jiang9, Xiaoqing Zhang10, Hu Yu, MD11
AFFILIATIONS
1 Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2 Sichuan Provincial People's Hospital, Chengdu, China
3 The First Hospital of Jilin University, Changchun, China
4 The First Affiliated Hospital of China Medical University, Shen Yang, China
5 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, WuHan, China
6 The First Affiliated Hospital of Guangxi Medical University, Nanning, China
7 Henan Cancer Hospital, Zhengzhou, China
8 Shanghai Hansoh BioMedical Co., Ltd, Shanghai, China
9 Shanghai Hansoh BioMedical Co., Ltd, Shanghai, China
10 Shanghai Hansoh BioMedical Co., Ltd, Shanghai, China
11 Union Hospital Tongji Medical college Huazhong University of Science and Technology, Wuhan, China
ABSTRACT
Introduction:
Although adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitors targeting the BCR::ABL1 ATP-binding site have significantly extended life expectancy in chronic phase chronic myeloid leukemia (CML-CP) patients, there remains an unmet need for new first-line therapies that are both effective and safe. HS-10382, a novel BCR::ABL1 allosteric inhibitor that specifically targets the ABL myristoyl pocket, demonstrated encouraging preclinical data. Here, we report preliminary results from a phase 1b study (CTR20242299) evaluating HS-10382 monotherapy in patients with newly diagnosed CML-CP.
Methods:
In this single-arm, open-label, multicenter study in China, adults with newly diagnosed BCR::ABL1-positive CML-CP (confirmed within 6 months) received oral HS-10382 160 mg twice daily in 28-day cycles. The primary objective was to evaluate safety and tolerability.
Results:
Patient Demographics and Disposition: From September to December 2025, 31 patients with newly diagnosed CML-CP were enrolled in the study. The median age was 47.0 years (range 20-65), 71.0% (22/31) were male, and all patients had ECOG performance status 0-1. According to ELTS risk evaluation at baseline, 77.4% (24/31) of patients were classified as low risk, 22.6% (7/31) as intermediate, and none as high. As of the data cutoff (May 22, 2026), the median follow-up time was 7.3 months (range 5.7-8.7). Safety: In the safety-evaluable population (N=31), the majority of treatment-emergent adverse events (TEAEs) were Grade 1-2. The most common TEAEs (incidence ≥10%) included platelet count decreased (48.4%, 15/31), white blood cell count decreased (32.3%, 10/31), neutrophil count decreased (25.8%, 8/31), hyperuricaemia (22.6%, 7/31), alanine aminotransferase increased (19.4%, 6/31), and lipase increased (16.1%, 5/31). Grade ≥3 TEAEs, mainly hematologic events, were observed in 29.0% (9/31) patients. Serious adverse events occurred in 12.9% (4/31) patients. No deaths were reported. Efficacy: In the efficacy-evaluable population (N=31), 90.3% (28/31) patients achieved a complete cytogenetic response rate at week 24 (95% CI, 74.3%-98.0%). The major molecular response (MMR, BCR::ABL1 transcript levels ≤0.1% on the International scale, IS) was achieved by 18 patients (58.1%; 95% CI, 39.1%-75.5%) at Week 24. The median time to MMR was 23.6 weeks (95% CI, 19.1-24.1).
Conclusions:
HS-10382 monotherapy exhibited a generally favorable safety profile and encouraging preliminary efficacy in patients with newly diagnosed CML-CP. These findings warrant further investigation in an expanded cohort with longer follow-up to assess long-term efficacy and safety.
DISCLOSURES
Weiming Li: No relevant conflicts of interest to declare.